tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Vohra S et al. Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial. 2016 Int. J. Dermatol. pmid:26147635
Herz S et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. 2016 Eur. J. Cancer pmid:27614165
Hazama Y et al. Effect of Physiological Changes in the Skin on Systemic Absorption of Tacrolimus Following Topical Application in Rats. 2016 Biol. Pharm. Bull. pmid:26934927
Anderson K et al. A retrospective analysis of pediatric patients with lichen sclerosus treated with a standard protocol of class I topical corticosteroid and topical calcineurin inhibitor. 2016 J Dermatolog Treat pmid:26138407
Nakajima A et al. Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis. 2016 Mod Rheumatol pmid:26934454
Pan GH et al. Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study. 2016 Oncotarget pmid:26933811
Moes DJ et al. Response: Limited sampling strategies for once daily tacrolimus exposure monitoring. 2016 Eur. J. Clin. Pharmacol. pmid:26931555
Merino D et al. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment. 2016 Immunology pmid:26931075
Lee SG et al. Enhanced topical delivery of tacrolimus by a carbomer hydrogel formulation with transcutol P. 2016 Drug Dev Ind Pharm pmid:26925849
Doke T et al. Post-Transplant Membranous Nephropathy Associated with Chronic Active Antibody-Mediated Rejection and Hepatitis C Infection after Deceased Donor Renal Transplantation. 2016 Intern. Med. pmid:26875963
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Lim SW et al. Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus. 2016 Sci Rep pmid:27436514
Knight SR Intrapatient variability in tacrolimus exposure - a useful tool for clinical practice? 2016 Transpl. Int. pmid:27283231
Shuker N et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. 2016 Transpl. Int. pmid:27188932
Rodrigues-Diez R et al. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. 2016 Sci Rep pmid:27295076
Wen X et al. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. 2016 Am. J. Transplant. pmid:27137884
Koura-Nishiura A et al. Clearance of atypical facial necrobiosis lipoidica with tacrolimus ointment. 2016 J Eur Acad Dermatol Venereol pmid:25353715
Lee SH et al. Low-dose mycophenolate mofetil in tablet form or capsule form combined with tacrolimus in the early period after kidney transplantation: a prospective randomized trial
. 2016 Clin. Nephrol. pmid:27781419
Nie F et al. [Post-transplant kidney from C-III donation after cardiac death of children: a clinicopathologic study of 20 cases]. 2016 Zhonghua Bing Li Xue Za Zhi pmid:26879429
Song JL et al. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation. 2016 World J. Gastroenterol. pmid:26877618
Viesselmann CW et al. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection. 2016 Pharmacotherapy pmid:26877191
Nascimento J and Machado S Pediatric-onset necrobiosis lipoidica. 2016 Pediatr Int pmid:26865027
Than NN et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. 2016 Scand. J. Gastroenterol. pmid:26458216
Wang X et al. Ureaplasma urealyticum Causes Hyperammonemia in an Experimental Immunocompromised Murine Model. 2016 PLoS ONE pmid:27537683
Ueno KI et al. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. 2016 Int J Rheum Dis pmid:27457756
Malik N et al. A simple office-based procedure for patients with extensive vitiligo. 2016 J. Am. Acad. Dermatol. pmid:27745651
Lee JH et al. Stability of tacrolimus solutions in polyolefin containers. 2016 Am J Health Syst Pharm pmid:26796907
Cruzado JM et al. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation. 2016 Transpl. Int. pmid:27648523
Torrisi JS et al. Inhibition of Inflammation and iNOS Improves Lymphatic Function in Obesity. 2016 Sci Rep pmid:26796537
Chatterjee S and Agrawal D Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis. 2016 Cornea pmid:27310883
Yan L et al. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. 2016 Pharmacogenomics pmid:26784512
Barreto P et al. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients. 2016 Transplant. Proc. pmid:27742278
Wu YJ et al. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. 2016 Ann. Transplant. pmid:26782179
Robinson CL et al. Posaconazole in lung transplant recipients: use, tolerability, and efficacy. 2016 Transpl Infect Dis pmid:26781986
Ward I et al. Digital Pulp Ulcerations and Inverse Gottron Papules in Melanoma Differentiation-Associated Gene 5-Related Dermatomyositis. 2016 J Clin Rheumatol pmid:27464773
EriÅŸ E et al. Evaluation of Effect of Topical Tacrolimus Treatment on Herpetic Stromal Keratitis in a Rat Model. 2016 Eye Contact Lens pmid:25996419
First MR et al. Use of low-dose tacrolimus and associated hypomagnesemia in the prevention of erectile dysfunction following prostatectomy for prostate cancer. 2016 Pharmacol Rep pmid:27607363
Rodríguez-Lago I et al. Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease. 2016 Rev Esp Enferm Dig pmid:27604685
Pereira M et al. Hyperacute Rejection in a Kidney Transplant With Negative Crossmatch: A Case Report. 2016 Transplant. Proc. pmid:27742303
Armand P et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. 2016 Br. J. Haematol. pmid:26729448
Rostaing L et al. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 2016 Am. J. Kidney Dis. pmid:26717860
Spain L et al. Management of toxicities of immune checkpoint inhibitors. 2016 Cancer Treat. Rev. pmid:26874776
Matsa E et al. Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. 2016 Cell Stem Cell pmid:27545504
Lee B et al. Appropriate timing of tacrolimus concentration measurements in the emergency department. 2016 Am J Health Syst Pharm pmid:27543574
Ocampo-Garza J et al. Acquired Hyperpigmentation and Cicatricial Alopecia. 2016 Am. J. Med. Sci. pmid:27524226
Solomon A Allergic manifestations of contact lens wearing. 2016 Curr Opin Allergy Clin Immunol pmid:27518840
Komaki Y et al. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. 2016 J Crohns Colitis pmid:26645641
Jung HJ et al. Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate. 2016 Int. J. Biol. Macromol. pmid:26642839
Vadcharavivad S et al. Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. 2016 J Clin Pharm Ther pmid:27191538
Elshatory YM et al. Diagnostic and Therapeutic Challenges. 2016 Retina (Philadelphia, Pa.) pmid:26225484
Thevissen K How promising are combinatorial drug strategies in combating Candida albicans biofilms? 2016 Future Med Chem pmid:27463947
Li X and Sun S Targeting the fungal calcium-calcineurin signaling network in overcoming drug resistance. 2016 Future Med Chem pmid:27463738
Ikeya K et al. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. 2016 J Crohns Colitis pmid:26581895
Gala-Lopez BL et al. Antiaging Glycopeptide Protects Human Islets Against Tacrolimus-Related Injury and Facilitates Engraftment in Mice. 2016 Diabetes pmid:26581595
Butts AR et al. Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation. 2016 J Oncol Pharm Pract pmid:25802301
Jung H et al. FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes. 2016 Pigment Cell Melanoma Res pmid:26581186
Belliere J et al. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia. 2016 Transpl. Int. pmid:26575959
Shao K et al. Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation. 2016 Scand. J. Immunol. pmid:26524694
Cena T et al. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients. 2016 Transpl. Int. pmid:27343849
Moes DJ et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. 2016 Eur. J. Clin. Pharmacol. pmid:26521259
Yeo L and Ormerod AD Oral tacrolimus: a treatment option for recalcitrant erosive lichen planus. 2016 Clin. Exp. Dermatol. pmid:27339859
Hashimoto K et al. Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus. 2016 Int. J. Hematol. pmid:27338269
Grönhagen CM and Tey HL Meralgia paresthetica successfully treated with topical 0.1% tacrolimus: a case report. 2016 Int. J. Dermatol. pmid:26518996
Korobko IV and Lomonosov KM A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo. 2016 Dermatol Ther pmid:27329330
Vadcharavivad S et al. Validation of a 2-Point Limited Sampling Strategy to Predict the Tacrolimus Area-Under-the-12-Hour-Curve in Kidney Transplant Recipients. 2016 Ther Drug Monit pmid:27328329
Wu H et al. Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice. 2016 PLoS ONE pmid:27606422
Gardiner KM et al. Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. 2016 Ann. Transplant. pmid:26729299
Chacon A and Mercer J Successful management of angiolymphoid hyperplasia with eosinophilia in a split-face trial of topical tacrolimus and timolol solution. 2016 G Ital Dermatol Venereol pmid:25014586
Grześk E et al. Cyclosporine-A, but not tacrolimus significantly increases reactivity of vascular smooth muscle cells. 2016 Pharmacol Rep pmid:26721374
McShane AJ et al. Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry. 2016 Clin. Chim. Acta pmid:26721314
Riegersperger M et al. The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients. 2016 Clin. Lab. pmid:28164520
Levitsky J et al. Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses. 2016 PLoS ONE pmid:27275747
Schneider L et al. Study of the Atopic March: Development of Atopic Comorbidities. 2016 Pediatr Dermatol pmid:27273433
Kostereva NV et al. IGF-1 and Chondroitinase ABC Augment Nerve Regeneration after Vascularized Composite Limb Allotransplantation. 2016 PLoS ONE pmid:27272754
Raja R et al. A prospective study of collapsing focal segmental glomerulosclerosis. 2016 Ren Fail pmid:27266801
De Meyer M et al. Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study. 2016 Pharmacogenomics pmid:27266721
Bagherani N Comparison of pimecrolimus with clobetasol propionate in the treatment of localized vitiligo. 2016 Dermatol Ther pmid:26445411
Ahmad M et al. Effectiveness of minocycline and FK506 alone and in combination on enhanced behavioral and biochemical recovery from spinal cord injury in rats. 2016 Pharmacol. Biochem. Behav. pmid:27106204
Sisti A et al. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. 2016 An Bras Dermatol pmid:27192518
Ramachandran R et al. Cyclical cyclophosphamide and steroids is effective in resistant or relapsing nephrotic syndrome due to M-type phospholipase A2 receptor-related membranous nephropathy after tacrolimus therapy. 2016 Kidney Int. pmid:27181781
Ha DH et al. Effects of tacrolimus on morphology, proliferation and differentiation of mesenchymal stem cells derived from gingiva tissue. 2016 Mol Med Rep pmid:27177273
Kim JM et al. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: A randomized prospective study. 2016 Liver Transpl. pmid:26360125
Bican Demir A et al. Two Cases With Developing Neurologic Complications After Liver Transplant. 2016 Exp Clin Transplant pmid:26643318
Al-Maawali AK et al. Modern Treatments and Stem Cell Therapies for Perianal Crohn's Fistulas. 2016 Can J Gastroenterol Hepatol pmid:28053967
Chang HK et al. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital. 2016 Transplant. Proc. pmid:27109981
Baraldo M Meltdose Tacrolimus Pharmacokinetics. 2016 Transplant. Proc. pmid:27109969
Pretagostini R et al. Delayed Introduction of Everolimus in De Novo Renal Transplanted Patients: A Single-Center Experience. 2016 Transplant. Proc. pmid:27109947
Zamorano-Leon JJ et al. New strategy of tacrolimus administration in animal model based on tacrolimus-loaded microspheres. 2016 Transpl. Immunol. pmid:27102446
Park OJ et al. A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter. 2016 Clin. Exp. Dermatol. pmid:26299799
Watanabe H et al. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. 2016 Lupus pmid:26296361
Gomes RM et al. Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. 2016 Expert Rev Clin Pharmacol pmid:27181131
Felix MJ et al. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens. 2016 Pharmacotherapy pmid:26799522
Vanhove T et al. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. 2016 Am. J. Transplant. pmid:27013142
Kanazawa H et al. Chemotherapy-induced B-cell depletion in hepatoblastoma patients undergoing ABO-incompatible living donor liver transplantation. 2016 Pediatr Transplant pmid:27012966
Shipley CA and Spivakovsky S Tacrolimus or clobetasol for treatment of oral lichen planus. 2016 Evid Based Dent pmid:27012570
Ko DH et al. Performance Evaluation of a Restored Dimension TACR Assay: An Automated Platform for Measuring the Whole Blood Tacrolimus Concentration. 2016 Clin. Lab. pmid:27012028
Tang JT et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. 2016 Expert Opin Drug Metab Toxicol pmid:27010623
Ha DH et al. Potential differentiation ability of gingiva originated human mesenchymal stem cell in the presence of tacrolimus. 2016 Sci Rep pmid:27721434
Taşoğlu Ö et al. Pregabalin: A New Adjunct in Calcineurin Inhibitor Pain Syndrome Treatment. 2016 Prog Transplant pmid:27312682
Tron C et al. A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. 2016 J Chromatogr A pmid:27837999